Published TCIMAIL newest issue No.197 | New tool "TCI SpectraViewer" | [Product Highlights] o-Nitrobenzyl Photolabile... | Product Document Searching Made Easy by 2D Code!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 198470-84-7 | Product Number: P2579
Parecoxib
×
![]()
×
Purity: >97.0%(T)(HPLC)
Synonyms:
- N-[[4-(5-Methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]propionamide
Product Documents:
| Size | Unit Price | Hyderabad | Japan* | Quantity |
|---|---|---|---|---|
| 50MG |
₹3,360.00
|
Contact Us | 20 |
|
| 250MG |
₹9,800.00
|
Contact Us | 19 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | P2579 |
| Purity / Analysis Method | >97.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__9H__1__8N__2O__4S = 370.42 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (<0°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 198470-84-7 |
| Reaxys Registry Number | 8640266 |
| Merck Index (14) | 7036 |
| MDL Number | MFCD08141856 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 97.0 area% |
| Purity(Neutralization titration) | min. 97.0 % |
| Melting point | 153.0 to 157.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 155 °C |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H360 : May damage fertility or the unborn child. H373 : May cause damage to organs through prolonged or repeated exposure. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | TX1478700 |
Transport Information:
Application
Parecoxib: A Selective Cyclooxygenase-2 (COX-2) Inhibitor
Parecoxib, a prodrug of valdecoxib [V0133], is a selective inhibitor of cyclooxygenase-2 (COX-2) which is an inducible isoform of COX. The mechanism of action is mainly by inhibition of the enzyme COX in the arachidonic acid metabolism pathway, resulting in reduced prostaglandin synthesis. In theory, a drug that selectively inhibited COX-2 might block inflammation, pain, and fever produced by prostaglandins while reducing the side effects (gastric erosions and ulcers) associated with inhibition of COX-1. The sodium salt is widely used for clinical. (The product is for research purpose only.)
References
- Parecoxib (parecoxib sodium)
- The second generation of COX-2 inhibitors: what advantages do the newest offer? (a review)
- Selective cyclooxygenase-2 inhibitors: similarities and differences
- Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology.
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.